This amendment confirms pricing stability at $5.00 per share despite prior uncertainty, but the increased warrant strike price suggests underwriter negotiation leverage. The lack of financial updates confirms the company remains pre-revenue with high execution risk. Traders should monitor for FDA trial progress and any signs of enrollment delays, which could pressure the stock post-IPO.
Executive Summary
Encore Medical, Inc. filed an amended S-1/A registration statement to update the filing fee table for its IPO, reflecting a revised exercise price of $6.00 per share for underwriter warrants (up from $5.00). The IPO remains structured to raise up to $17.25 million by offering 3.45 million shares at $5.00 per share, including over-allotment. The company is a pre-revenue medical device firm developing a PFO closure device for stroke and migraine, with CE Mark approval but no U.S. FDA clearance yet.
Key Financial Metrics
Key Facts
- IPO offering of 3.45 million shares (3M base + 450K over-allotment) at $5.00 per share, raising up to $17.25 million
- Underwriter warrants to purchase 276,000 shares now have an exercise price of $6.00 per share (up from $5.00), requiring an additional $38.12 in filing fees
- Company has CE Mark approval for its PFO closure device but lacks FDA approval for U.S. commercialization
- Relies on related party Cardia, Inc. for manufacturing and has a history of net losses and negative cash flows
- Proceeds will fund U.S. clinical trials, debt repayment, and working capital
Financial Impact
Up to $17.25 million in gross proceeds at $5.00 per share, with $13.8 million net to the company after underwriting discounts
Risk Factors
- High risk of clinical trial failure or FDA rejection for the PFO device
- Heavy reliance on a single related-party manufacturer (Cardia, Inc.)
- Going concern uncertainty due to historical losses and limited cash runway
- Dilution risk from future financings if IPO proceeds are insufficient
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001104659-26-039715 |
| Document: tm2525595d16_ex4-3.htm | 0001104659-26-039715 |
| Document: tm2525595d15_ex-filingfees.htm | 0001104659-26-039715 |
| Document: 0001104659-26-039715-index-headers.html | 0001104659-26-039715 |
| Document: 0001104659-26-039715-index.html | 0001104659-26-039715 |
| Document: 0001104659-26-039715.txt | 0001104659-26-039715 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 28d ago | S-1/A | — | awaiting T+20 | — | — |
Aug 10, 2026 11w ago | S-1/A | — | awaiting T+20 | — | — |
Jul 1, 2026 16w ago | S-1/A | — | awaiting T+20 | — | — |
Apr 3, 2026 29w ago | S-1/A | — | awaiting T+20 | — | — |
Mar 24, 2026 30w ago | S-1/A | — | awaiting T+20 | — | — |
Mar 3, 2026 33w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers